CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04933968
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:27.991557+00:00
Published At: 2024-06-06T00:00:00+00:00
Record Updated At: 2024-06-06
Results Posted At: 2024-06-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Respiratory Tract Viral Infections", "Human Metapneumovirus (hMPV) Infection", "Parainfluenza (PIV) Infection", "Respiratory Syncytial Viral (RSV) Infection", "Influenza Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-06-06"
protocolSection.identificationModule.nctId: "NCT04933968"
protocolSection.identificationModule.officialTitle: "Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-06-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.